ClinicalTrials.gg
RecruitingNCT05641831Updated Jan 2, 2026

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

A Phase 2 interventional study of Biospecimen Collection and Bone Marrow Aspiration and Biopsy in Clonal Cytopenia of Undetermined Significance, sponsored by Uma Borate. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-02.

Sponsored by Uma Borate · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Cytopenia with a site in United States — 17 open to participants now, 22 under way, 2 of them phase 3. Cytopenia · United States.

Planned enrollment
7th of 32
110 · median 33
Started
2023
with 2 others
Phase 2
13 of 51
8 open now
Primary completion
2028-12
later than 10 of 20 live
Registered
40th of 51
by date

Among the 51 studies in Cytopenia with a site in United States, this one is the 7th largest by planned enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2023, is one of 13 in phase 2, reaches primary completion later than 10 of the 20 other live ones, and was the 40th registered.

Cytopenia

81 studies on the registry are indexed under Cytopenia; 25 are open to participants now.

Browse Cytopenia studies →

Open to participants now

17 of the 51 studies in Cytopenia with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Cytopenia studies recruiting now, 17 (85%) set no upper age limit and 1 (5%) stops at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Cytopenia with a site in United States, or all of them as a file.
02

Study summary

This phase II trial tests how well canakinumab works to prevent progression to cancer in patients with clonal cytopenias of unknown significance (CCUS). CCUS is a blood condition defined by a decrease in blood cells. Blood cells are composed of either red blood cells, white blood cells, or platelets. In patients with CCUS, blood counts have been low for a long period of time. Patients with CCUS also have a mutation in one of the genes that are responsible for helping blood cells develop. The combination of genetic mutations and low blood cell counts puts patients with CCUS at a higher risk to develop blood cancers in the future. This transformation from low blood cell counts to cancer may be caused by inflammation in the body. Canakinumab is a monoclonal antibody that may block inflammation in the body by targeting a specific antibody called the anti-human interleukin-1beta (IL-1beta).

Read the detailed description

PRIMARY OBJECTIVE:

I. To evaluate the length of time until development of a myeloid neoplasm (ie myelodysplastic syndrome [MDS], myeloproliferative neoplasm [MPN], chronic myelomonocytic leukemia [CMML], or acute myeloid leukemia [AML]) in high-risk clonal cytopenia of undetermined significance (CCUS) patients receiving canakinumab as therapeutic intervention compared to the control arm.

SECONDARY OBJECTIVES:

I. To determine the effect of canakinumab on hematological overall response rate.

II. To determine the effect of canakinumab on complete hematological response rate.

III. To determine the effect of canakinumab on response duration. IV. To determine the effect of canakinumab on overall survival. V. To determine the effect of canakinumab on mutational burden. VI. To determine the effect of canakinumab on infection-related adverse events. VII. To determine the effect of canakinumab on recovery of blood cell populations.

VIII. To determine the effect of canakinumab on cardiovascular episodes compared to a control arm.

IX. Patient reported outcomes will be collected using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C3).

EXPLORATORY OBJECTIVES:

I. To quantify changes in the bone marrow (BM) microenvironment according to immune cell constitution and cytokine levels over the course of canakinumab treatment compared to a control arm.

II. To characterize the inflammatory milieu in peripheral blood (PB) and BM samples by serial measurement and characterization of key cytokines (IL-1, IL-2, IL-6, TNF alpha and beta, and IFN-gamma), sensitivity of patient samples to these cytokines and relationships to various genes involved in clonal hematopoiesis.

III. To determine the dynamics of change in clone size of various CH genes in serial patient treatment and control samples, during the study, by a variety of assays including single cell sequencing, copy number alterations, and variant allele frequency (VAF) measurement to characterize differences in disease evolution.

IV. To collect serial measurement of immune cell populations in PB and BM of serial patient treatment and control samples, during the study, to characterize various immune cells involving both the innate and adaptive immune system including natural killer (NK) cell, T cell subsets namely effector, regulatory and memory T cells as well as various cell surface molecules such as checkpoint modulators (PD-1/PD-L1/TIM-3, LAG-3).

V. To understand the effect of global effects on the BM microenvironment of CH status/post (s/p) canakinumab treatment compared to the control patients using ribonucleic acid (RNA) sequencing and global methylation assays to further characterize unique genomic signatures in these patients.

OUTLINE: Patients are randomized to one of two arms.

ARM I: Patients receive canakinumab subcutaneously (SC) on study.

ARM II: Patients receive placebo SC on study.

All patients also undergo echocardiogram (ECHO) and chest x-ray during screening, collection of blood samples during screening and follow up, and bone marrow biopsy and aspiration throughout the trial.

03

Conditions studied

  • Clonal Cytopenia of Undetermined Significance

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with age >= 18 with high-risk CCUS
  • Must meet ALL the following criteria:

    • Unexplained, cytopenias (greater than 4 months) in one or more of the following lineages: erythroid cells, neutrophils, . Clinically meaningful cytopenia is institution specific and threshold may vary on age, sex, and race. Decision-making should depend upon lab values specific to the institution and supersede public works. Based upon published work, significant cytopenias are defined as the following (must meet criteria in at least one lineage):

      • Erythroid Cells:

        • \< 11 g/dL
      • White Blood Cells:

        • \< 1800/microL and > 500/microL
      • Platelets:

        • Platelet Count \< 150,000/microL and > 50,000/microL
    • MDS criteria not fulfilled
    • No other evidence of hematological
    • No or only mild (\< 10%) bone marrow dysplasia
    • Blast cells \< 5% detected via morphologic examination of blood and/or bone marrow smears which can also be supported by flow cytometry and/or immunohistochemical studies
    • Any of the following:

      • Isolated somatic spliceosome mutation at any VAF (SRSF2, SF3B1, U2AF1, or ZRSR2)
      • Isolated TP53 mutation greater than 5% VAF
      • At least 1 mutation in TET2, DMNT3A, or ASXL1 at any VAF coupled with at least 1 other known myeloid pathogenic somatic mutation or known pathogenic germline mutation that predisposes to myeloid malignancy as determined by next generation sequencing and bone marrow
      • A TET2, DMNT3A, or ASXL1 greater than 10% VAF coupled with another TET2, DMNT3A, or ASXL1 greater than 10% VAF
      • The presence of two or more known myeloid pathogenic somatic or germline mutations (other than TET2, ASXL1, DMNT3A, TP53, or spliceosome mutations) greater than 10% VAF
  • Ability to understand and willingness to sign the written document
  • (ECOG) performance status 0, 1, or 2
  • Patients with a history of hypertension or active hypertension are strongly encouraged to optimize blood pressure control
  • greater than 45 ml/min using Cockcroft-Gault
  • Total =\< 1.5 x
  • (AST) \< 3 x ULN
  • Alanine transaminase (ALT) \< 3 x ULN

Exclusion criteria

Exclusion Criteria:

  • Concurrent requiring active systemic therapy
  • Diagnosis of MDS or any other myeloid malignancy in the patient's lifetime
  • History of to canakinumab or drug of a similar class
  • Active infection requiring prompt evaluation and treatment or history of recurrent infections
  • Known active or recurrent hepatic disorder including cirrhosis, and C (via positive or indeterminate central laboratory [lab] results)
  • Subjects with active tuberculosis. In subjects with a history of tuberculosis but without active tuberculosis, if the results of the evaluation require treatment per local guidelines, then the treatment should be initiated before randomization (unless otherwise required by Health Authorities or Institutional Review Board (IRB) in which case curative treatment must be completed prior to screening)
  • Subjects with suspected or proven state or infections. If the results of this screening per local treatment guidelines or clinical practice require treatment for said infection then the patient is not eligible. Suspected or proven immunocompromised states or infections include:

    • Those with any other medical condition such as active infection, treated or untreated, which in the opinion of the investigator places the subject at an unacceptable risk for participation in immunomodulatory therapy. If in the opinion of the investigator, the patient's immunocompromised state does not pose an unacceptable risk for participation, in the absence of uncontrolled infection, and the patient does not have a history of serious infections (such as tuberculosis); then the patient may participate in this study.
    • Known history of testing positive for (HIV) infections. For countries where HIV status is mandatory: testing positive for HIV during screening using a local test.
    • Allogeneic bone marrow or solid organ transplant (history of any or within a certain period of time?)
    • Those requiring systemic or local treatment in doses with systemic effects e.g.:

      • Prednisone > 20 mg (or equivalent) oral or intravenous daily for > 14 days
      • Prednisone > 5 mg and =\< 20 mg (or equivalent) daily for > 30 days
      • Equivalent dose of methotrexate > 15 mg weekly
      • Note: Azathioprine is allowed. Daily -replacement for conditions such as adrenal or pituitary insufficiency is allowed. Topical, inhaled or local steroid use in doses that are not considered to cause systemic effects are permitted. Steroids for pre-medication related to chemotherapy as per local standard of care are permitted.
  • Live or attenuated vaccination within 3 months prior to first dose of study drug (e.g. Measles/Mumps/Rubella [MMR], Yellow Fever, Rotavirus, Smallpox, etc.) and after initiation of canakinumab treatment
  • Use of erythropoietin stimulating agents (ESA) or growth factors within four weeks prior to the start of the study
  • Pregnant or nursing women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test. Women of , defined as all women physiologically capable of becoming pregnant, unless they are using basic methods of during dosing of study treatment and for up to 130 days after last dose of study drug. Basic contraception methods include:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least 6 weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
    • Male sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject
    • Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps). For UK: with spermicidal foam/gel/film/cream/ vaginal suppository
    • Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \< 1%), for example hormone vaginal ring or transdermal hormone contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS). In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment. Prior to entry into this study, cisplatin-based chemotherapy, which may be toxic to the fetus, may be given. The time between the end of cisplatin-based chemotherapy and the start canakinumab/placebo treatment is variable, resulting in a variable need for continuation of highly effective contraception. Women are considered and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least six weeks prior to first dose of study drug. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential. If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the Form (ICF).
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    ARM I (canakinumab)

    Patients receive canakinumab SC on study. All patients also undergo ECHO and chest x-ray during screening, collection of blood samples during screening and follow up, and bone marrow biopsy and aspiration throughout the trial.

    Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration and Biopsy · Drug: Canakinumab · Procedure: Chest Radiography · Procedure: Echocardiography · Other: Quality-of-Life Assessment

  • Placebo comparator
    ARM II (placebo)

    Patients receive placebo SC on study. All patients also undergo ECHO and chest x-ray during screening, collection of blood samples during screening and follow up, and bone marrow biopsy and aspiration throughout the trial.

    Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration and Biopsy · Procedure: Chest Radiography · Procedure: Echocardiography · Drug: Placebo Administration · Other: Quality-of-Life Assessment

Interventions

  • ProcedureBiospecimen Collection

    Undergo peripheral blood collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureBone Marrow Aspiration and Biopsy

    Undergo bone marrow biopsy and aspiration

  • Given SC

    Also known as: ACZ885, Ilaris

  • ProcedureChest Radiography

    Undergo chest x-ray

    Also known as: Chest X-ray

  • ProcedureEchocardiography

    Undergo ECHO

    Also known as: EC

  • DrugPlacebo Administration

    Given SC

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

06

What researchers measure

Primary outcomes

  1. Time to overt myeloid malignancy

    Will be estimated with the non-parametric Kaplan-Meier method to compute the median time as well as the percentage of study participants with a diagnosed hematologic malignancy of myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), chronic myelomonocytic leukemia (CMML)/ acute myeloid leukemia (AML) at landmark time points (e.g., 1-year, 2-years) with corresponding 95% confidence intervals. Since this method will censor patients who die without having developed MDS/MPN/CMML/AML, we will also compute the cumulative incidence of overt myeloid malignancy that accounts for the competing risk of death in the absence of a hematologic malignancy. All randomized patients will be included in the primary endpoint analysis in the arm to which they were randomized (ie, intent-to-treat population).

    Time frame: From the date of randomization until the first date of overt myeloid malignancy diagnosis, assessed up to 6 years

Secondary outcomes

  1. Hematological overall response rate

    Number of patients that achieve response divided by the number or randomized patients. Will be summarized using the method of Kaplan-Meier but also using the cumulative incidence function which would treat death in the absence of documented relapse as a completing risk.

    Time frame: 6 month assessment

  2. Complete hematological response rate

    Number of patient that achieve complete response divided by the number of randomized patients. Will be summarized using the method of Kaplan-Meier but also using the cumulative incidence function which would treat death in the absence of documented relapse as a completing risk.

    Time frame: 6 month assessment

  3. Duration of hematological response

    Will be summarized using the method of Kaplan-Meier but also using the cumulative incidence function which would treat death in the absence of documented relapse as a completing risk.

    Time frame: From the date of first documented hematological response until the date of documented diagnosis of MDS, MPN, CMML, or AML, assessed up to 6 years

  4. Overall survival

    Will be estimated using the method of Kaplan-Meier and estimates at landmark time points (e.g., 1-year, 2-years) will be provided with corresponding 95% confidence intervals.

    Time frame: From the date of registration until the date of death from any cause, assessed up to 6 years

  5. Changes in variant allele frequencies (VAFs) of somatic mutations

    Will be assessed by bone marrow biopsy (BMBx) samples with next generation sequencing (NGS). VAFs will be analyzed as a continuous variable and as the proportion of patients with at least a 50% of reduction in VAFs of somatic mutations relative to baseline using an Ion Torrent platform.

    Time frame: Up to 6 years

  6. Infection-related adverse event rates

    The number of patients who have an adverse event of interest divided by the number of patients who have adverse events assessed.

    Time frame: Up to 6 years

  7. Recovery of blood cell populations

    Changes in the percentages of lymphocytes and specific sub-types (ie T-cells) as well as erythroid, platelet, and neutrophil response via 2016 World Health Organization (WHO) International Working Group (IWG) hematological improvement criteria before and after therapy as assessed in bone marrow (BM) and hematological samples.

    Time frame: Up to 6 years

  8. Cardiovascular episodes

    The number of patients who has a cardiovascular event of interest divided by the number of patients who have adverse events assessed.

    Time frame: Up to 6 years

  9. Patient reported outcomes

    Outcomes reported using EORTC QLQ-C30 and compared between the two arms.

    Time frame: Up to 6 years

07

Study locations

6 of 6 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2023 (actual). Primary completion is estimated for Dec 2028, 70 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2022
First posted
Dec 8, 2022
StartActual
Feb 6, 2023
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Jan 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05641831
Lead sponsor
Uma Borate
Responsible party
Uma Borate (Principal Investigator, Ohio State University Comprehensive Cancer Center) — Sponsor-investigator
First posted
Dec 8, 2022
Start date
Feb 6, 2023
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jan 2, 2026

Study contacts

The Ohio State University Comprehensive Cancer Center
Contact
OSUCCCClinicaltrials@osumc.edu
800-293-5066
Uma M Borate, MD, MS
principal investigator · Ohio State University Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Canakinumab

Start the discussion